ClinicalTrials.gg

Program

coprelotamab

Also written as “GB221”, “GB221,2 mg/kg” and “GB221,6 mg/kg”.

Its studies are mostly in Breast Neoplasms · Spinal Muscular Atrophies of Childhood, led by 2 companies.

Furthest: phase 3, since Nov 13, 20195 company-led studies, 1 open or runningNext primary completion: Dec 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Edding Genor Group40 open or runningphase 3since Nov 13, 2019Nov 12, 2019none ahead
Gemma Biotherapeutics11 open or runningphase 2since May 30, 2025May 30, 2025Dec 2028phase 2 · NCT07070999

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2019First study: phase 1 study in Breast NeoplasmsNew to Edding Genor GroupEdding Genor Group · NCT04175171 · 32 enrolled · Australia
  2. Nov 12, 2019Phase 2 study in HER2-positive Breast CancerEdding Genor Group · NCT04170595 · 132 enrolled · China
  3. Nov 13, 2019Phase 3 study in HER-2-positive Advanced Breast CancerEdding Genor Group · NCT04164615 · 336 enrolled · China
  4. Mar 2, 2021Phase 1 study in Breast NeoplasmsEdding Genor Group · NCT04905667 · 87 enrolled · China
  5. May 30, 2025Gemma Biotherapeutics's first study: phase 2 study in Spinal Muscular Atrophies of ChildhoodNew to Gemma BiotherapeuticsGemma Biotherapeutics · NCT07070999 · 22 planned · Brazil

Ahead

  1. Dec 2028Primary completion: phase 2 study in Spinal Muscular Atrophies of ChildhoodGemma Biotherapeutics · NCT07070999

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07070999Spinal Muscular Atrophies of Childhood · Brazil2RecruitingGemma BiotherapeuticsDec 202822
NCT04905667Breast Neoplasms · China1CompletedEdding Genor GroupSep 8, 202087
NCT04164615HER-2-positive Advanced Breast Cancer · China3UNKNOWNEdding Genor GroupJul 2020336
NCT04175171Breast Neoplasms · Australia1CompletedEdding Genor GroupJan 8, 201232
NCT04170595HER2-positive Breast Cancer · China2UNKNOWNEdding Genor GroupDec 2021132

How it is read

Names in the registry

  • “GB221”, 3 entries
  • “GB221,2 mg/kg”, 1 entry
  • “GB221,6 mg/kg”, 1 entry
  • “GB221,8mg/kg”, 1 entry
  • “GB221:2mg/kg and Capecitabi:1000mg/kg”, 1 entry

Codes read as this program: GB221.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.